- Home
- KW vs SNDX Comparison
KW vs SNDX Comparison
Compare KW & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KW
- SNDX
- Stock Information
- Founded
- KW 1977
- SNDX 2005
- Country
- KW United States
- SNDX United States
- Employees
- KW N/A
- SNDX N/A
- Industry
- KW Real Estate
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- KW Finance
- SNDX Health Care
- Exchange
- KW Nasdaq
- SNDX Nasdaq
- Market Cap
- KW 1.4B
- SNDX 1.2B
- IPO Year
- KW 1992
- SNDX 2016
- Fundamental
- Price
- KW $8.54
- SNDX $12.01
- Analyst Decision
- KW Hold
- SNDX Strong Buy
- Analyst Count
- KW 1
- SNDX 10
- Target Price
- KW $13.00
- SNDX $36.20
- AVG Volume (30 Days)
- KW 791.1K
- SNDX 1.6M
- Earning Date
- KW 05-07-2025
- SNDX 03-03-2025
- Dividend Yield
- KW 5.64%
- SNDX N/A
- EPS Growth
- KW N/A
- SNDX N/A
- EPS
- KW N/A
- SNDX N/A
- Revenue
- KW $511,600,000.00
- SNDX $23,680,000.00
- Revenue This Year
- KW $32.54
- SNDX $274.86
- Revenue Next Year
- KW $45.44
- SNDX $130.47
- P/E Ratio
- KW N/A
- SNDX N/A
- Revenue Growth
- KW N/A
- SNDX N/A
- 52 Week Low
- KW $8.02
- SNDX $11.63
- 52 Week High
- KW $11.88
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- KW 39.79
- SNDX 35.22
- Support Level
- KW $8.68
- SNDX $12.70
- Resistance Level
- KW $9.07
- SNDX $13.80
- Average True Range (ATR)
- KW 0.29
- SNDX 0.67
- MACD
- KW -0.03
- SNDX -0.08
- Stochastic Oscillator
- KW 19.64
- SNDX 14.45
About KW Kennedy-Wilson Holdings Inc.
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.